Swing Trade Stock Picks

[Michael DeVries]

This is a Topic for you to Share and Discuss your favorite Swing Trading Stock Picks.

Please find some of my past Swing Trading Stock Picks at: http://blog.thevcf.com/forums/topic/stock-picks/

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 03/13/2017 – 03/17/2017:

1) TKAI – Tokai Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $0.73
b. Sell at >~ $1.80
c. Catalysts:
1. Merger with Otic Pharma Ltd; 20170101; 20170630; http://seekingalpha.com/filing/3366062#D307733DPREM14A_HTM_TOC307733_5
2. Merger may be terminated if the Otic Transaction is not consummated by April 30, 2017; 20170301; 20170430; http://seekingalpha.com/filing/3366062#D307733DPREM14A_HTM_TOC307733_5

2) CYCC – Cyclacel Pharmaceuticals Inc
a. Buy at < ~ $3.42
b. Sell at >~ $5.60
c. Catalysts:
1. A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors; 20180701; 20180731; https://www.clinicaltrials.gov/ct2/show/NCT00999401?term=Cyclacel&recr=Open&rank=2
2. Q4 2016 Cyclacel Pharmaceuticals Inc Earnings Release (Estimated)
-; 20170322; 20170322; https://www.google.com/finance?q=CYCC
3. Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) Phase 2; 20190701; 20190731; https://www.clinicaltrials.gov/ct2/show/NCT01253460?term=Cyclacel&rank=11
4. Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (ROSCO-CF); 20180801; 20181031; https://www.clinicaltrials.gov/ct2/show/NCT02649751?term=Cyclacel&recr=Open&rank=3

3) OASM – Oasmia Pharmaceutical AB
a. Buy at < ~ $1.65
b. Sell at >~ $2.50
c. Catalysts:
1. 1. Doxophos appr. Russia. 2. Apealea appr. Europe (ovarian cancer & metastatic breast cancer) 3. Comm. agreement Apealea 4. Positive cash flow 5. Several license agreements of nano technology XR17 (similar to Celator) and lots more to come; 20170101; 20171231; https://stocktwits.com/swedetrader/message/76192391
2. “@PeyoteBetting Hopefully a permission from EMA for sale of Paclical in Europe. Meeting scheduled in March”; 20170301; 20170331;
3. European approvals expected during spring 2017 for indications ovarian cancer & metastatic breast cancer; 20170301; 20170630; http://stocktwits.com/message/77020751

4) MICT – Micronet Enertec Technologies Inc – Trading Below Cash
a. Buy at < ~ $1.14
b. Sell at >~ $1.58

5) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.17
b. Sell at >~ $2.45
c. Catalysts:
1. Top Image Systems to Present at 29th Annual ROTH Conference on March 14th, 2017; 20170314; 20170314; http://finance.yahoo.com/news/top-image-systems-present-29th-140000745.html

6) GENE – Genetic Technologies Limited (ADR)
a. Buy at < ~ $1.04
b. Sell at >~ $2.70
c. Catalysts:
1. Genetic Technologies is expected to post its validation study for the test within six months; 20170101; 20170630; http://seekingalpha.com/article/4033099-genetic-technologies-catalysts-tremendous-upside

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 03/13/2017 - 03/17/2017, and Why?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 03/20/2017 – 03/24/2017:

1) GALE – Galena Biopharma Inc
a. Buy at < ~ $0.53
b. Sell at >~ $3.15

2) TKAI – Tokai Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $0.73
b. Sell at >~ $1.80
c. Catalysts:
1. Merger with Otic Pharma Ltd; 20170101; 20170630; http://seekingalpha.com/filing/3366062#D307733DPREM14A_HTM_TOC307733_5
2. Merger may be terminated if the Otic Transaction is not consummated by April 30, 2017; 20170301; 20170430; http://seekingalpha.com/filing/3366062#D307733DPREM14A_HTM_TOC307733_5

3) CYCC – Cyclacel Pharmaceuticals Inc
a. Buy at < ~ $3.42
b. Sell at >~ $5.60
c. Catalysts:
1. A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors; 20180701; 20180731; https://www.clinicaltrials.gov/ct2/show/NCT00999401?term=Cyclacel&recr=Open&rank=2
2. Q4 2016 Cyclacel Pharmaceuticals Inc Earnings Release (Estimated)
-; 20170322; 20170322; https://www.google.com/finance?q=CYCC
3. Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) Phase 2; 20190701; 20190731; https://www.clinicaltrials.gov/ct2/show/NCT01253460?term=Cyclacel&rank=11
4. Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (ROSCO-CF); 20180801; 20181031; https://www.clinicaltrials.gov/ct2/show/NCT02649751?term=Cyclacel&recr=Open&rank=3

4) OASM – Oasmia Pharmaceutical AB – American Depositary Shares
a. Buy at < ~ $1.65
b. Sell at >~ $2.50
c. Catalysts:
1. 1. Doxophos appr. Russia. 2. Apealea appr. Europe (ovarian cancer & metastatic breast cancer) 3. Comm. agreement Apealea 4. Positive cash flow 5. Several license agreements of nano technology XR17 (similar to Celator) and lots more to come; 20170101; 20171231; https://stocktwits.com/swedetrader/message/76192391
2. “@PeyoteBetting Hopefully a permission from EMA for sale of Paclical in Europe. Meeting scheduled in March”; 20170301; 20170331;
3. European approvals expected during spring 2017 for indications ovarian cancer & metastatic breast cancer; 20170301; 20170630; http://stocktwits.com/message/77020751

5) MICT – Micronet Enertec Technologies Inc – Trading Below Cash
a. Buy at < ~ $1.14
b. Sell at >~ $1.58

6) PRTO – Proteon Therapeutics Inc – Trading Below Cash
a. Buy at < ~ $1.58
b. Sell at >~ $2.60
c. Catalysts:
1. A new clinical trial … hopes to enroll 500 before the end of 2017; 20170317; 20171231; http://www.bizjournals.com/kansascity/news/2017/03/17/proteon-therapeutics-vonapanitase-new-stage3-trial.html?ana=yahoo
2. Phase 3 enrollment to be completed 1Q 2017. Data due 2Q 2018. – Vonapanitase (PRT-201) PATENCY-2 – Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF) – Phase 3; 20170101; 20170331; http://ir.proteontherapeutics.com/phoenix.zhtml?c=253625&p=irol-newsArticle&ID=2229192
3. Phase 3 enrollment to be completed 1Q 2017. Data due 2Q 2018. – Vonapanitase (PRT-201) PATENCY-2 – Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF) – Phase 3; 20180401; 20180630; http://ir.proteontherapeutics.com/phoenix.zhtml?c=253625&p=irol-newsArticle&ID=2229192
4. Proteon Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference March 22nd; 20170322; 20170322; http://finance.yahoo.com/news/proteon-therapeutics-present-oppenheimer-27th-115500386.html

7) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.17
b. Sell at >~ $2.45

8) GENE – Genetic Technologies Limited (ADR)
a. Buy at < ~ $1.04
b. Sell at >~ $2.70
c. Catalysts:
1. Genetic Technologies is expected to post its validation study for the test within six months; 20170101; 20170630; http://seekingalpha.com/article/4033099-genetic-technologies-catalysts-tremendous-upside

9) TROV – TrovaGene Inc – Trading Below Cash
a. Buy at < ~ $1.25
b. Sell at >~ $1.50

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 03/20/2017 - 03/24/2017, and Why?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 04/10/2017 – 04/14/2017:

1) GALE – Galena Biopharma Inc – Trading Below Cash
a. Buy at < ~ $0.53
b. Sell at >~ $3.15

2) GNMX – Medgenics Inc
a. Buy at < ~ $1.50
b. Sell at >~ $4.00
c. Catalysts:
1. Multiple trails to complete / Catalysts by EOY 2017; 20170321; 20171231; http://aevigenomics.com/c/pipeline/index.php

3) TEAR – TearLab Corp – Trading Below Cash
a. Buy at < ~ $1.85
b. Sell at >~ $3.80
c. Catalysts:
1. Brazil registration being prepared with approval expected in 2017; 20170401; 20171231; https://www.tearlab.com/pdfs/Investor_Deck_April_12_2016.pdf&ved=0ahUKEwjBh7XJkIPTAhXDbxQKHamVCUkQFggfMAE&usg=AFQjCNEKRfW9rZ8OVqPr90z1BUdKJZogbw&sig2=wUP5_4hRdr5-LwiorihWxQ
2. New platform launch in 2017 will drive higher revenue and margins; 20170401; 20171231; https://www.tearlab.com/pdfs/Investor_Deck_April_12_2016.pdf&ved=0ahUKEwjBh7XJkIPTAhXDbxQKHamVCUkQFggfMAE&usg=AFQjCNEKRfW9rZ8OVqPr90z1BUdKJZogbw&sig2=wUP5_4hRdr5-LwiorihWxQ

4) AVEO – AVEO Pharmaceuticals, Inc.
a. Buy at < ~ $0.50
b. Sell at >~ $0.97
c. Catalysts:
1. Phase 3 enrollment to be completed June 2017. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20170601; 20170630; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868
2. initial results from the Opdivo combination TiNivo study in RCC in the first half of 2017; 20170401; 20170630; https://seekingalpha.com/instablog/44479986-leny-hettmansperger/4974435-aveo-59c-insiders-recently-purchased-almost-10m-share-lots-significant-catalysts-upside-ahead?uprof=45&isDirectRoadblock=true
3. Phase 1/2 initiation of dosing announced March 22, 2017. Phase 1 part of trial data due 1H 2017. – Tivozanib + Opdivo – Renal cell cancer (RCC) – Phase 1/2; 20170630; 20170630; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255714
4. Top-line data due 1Q 2018. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20180101; 20180331; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868
5. Futility analysis due mid-2017. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20170630; 20170930; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868

5) SRNE – Sorrento Therapeutics Inc
a. Buy at < ~ $2.90
b. Sell at >~ $4.67
c. Catalysts:
1. Potential LA Cell (iTAb) partnership; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
2. AntiPD1 Antibody – big licensing deal with Servier – will be in clinic 2H 2017; 20170701; 20171231; https://twitter.com/DrSManian
3. Biosimilars Erbitux 1.2Billion Remicade 6.6Billion Xolair 0.8Billion – combined huge market potential; FDA in 1H’17; 20170101; 20170630; https://twitter.com/DrSManian
4. STI-001 regulatory pathway and discussions with FDA in 2017; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
5. IND filing for c-MET ADC expected in 2017 / 2018; 20170701; 20181231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
6. 3 clinical programs in 2017 w/ promising human &
in vivo proof-of-concept data; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
7. STI-A1014 PD-L1 mAb IND filing in 2017 in CN; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf

6) OASM – Oasmia Pharmaceutical AB – American Depositary Shares
a. Buy at < ~ $1.65
b. Sell at >~ $2.50
c. Catalysts:
1. 1. Doxophos appr. Russia. 2. Apealea appr. Europe (ovarian cancer & metastatic breast cancer) 3. Comm. agreement Apealea 4. Positive cash flow 5. Several license agreements of nano technology XR17 (similar to Celator) and lots more to come; 20170101; 20171231; https://stocktwits.com/swedetrader/message/76192391
2. European approvals expected during spring 2017 for indications ovarian cancer & metastatic breast cancer; 20170301; 20170630; http://stocktwits.com/message/77020751

7) MICT – Micronet Enertec Technologies Inc
a. Buy at < ~ $1.12
b. Sell at >~ $1.58

8) TCON – TRACON Pharmaceuticals Inc
a. Buy at < ~ $3.60
b. Sell at >~ $7.00
c. Catalysts:
1. Phase 2 data of TRC105 and Nexavar for Hepatocellular carcinoma due 2017; 20170101; 20171231; http://ir.traconpharma.com/phoenix.zhtml?c=253885&p=irol-newsArticle&ID=2169453
2. Small molecule inhibitor of mutated and wild-type Androgen Receptor • Expect Phase 1/2 dosing in 1H 2017; 20170401; 20170630; http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MzczNTYwfENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=636270019327888891
3. PHASE 2 in GBM detailed data expected mid-2017; 20170401; 20170930; http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MzczNTYwfENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=636270019327888891

9) TROV – TrovaGene Inc – Trading Below Cash
a. Buy at < ~ $0.90
b. Sell at >~ $1.50
c. Catalysts:
1. Phase II study planned with first patient to be dosed in 2017; 20170101; 20171231; https://seekingalpha.com/article/4058462-trovagene-trov-investor-presentation-slideshow

10) XENE – Xenon Pharmaceuticals Inc
a. Buy at < ~ $3.65
b. Sell at >~ $7.50
c. Catalysts:
1. Genentech anticipates initiating a Phase 2 clinical trial in 2017 for the potential treatment of pain; 20170101; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
2. Phase 2b clinical trial of TV-45070 topline results expected in mid-2017.; 20170401; 20170930; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
3. Xenon expects to file an investigational new drug (IND) application in the fourth quarter of 2017; 20171001; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 04/10/2017 – 04/14/2017, and Why?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 04/17/2017 – 04/21/2017:

1) GALE – Galena Biopharma Inc – Trading Below Cash
a. Buy at <~ $0.53
b. Sell at >~ $3.15

2) AVGR – Avinger Inc – Trading Below Cash
a. Buy at <~ $0.50
b. Sell at >~ $1.50
c. Catalysts:
1. In-Stent Restenosis Trial final results are expected to be released by the end of June 2017; 20170601; 20170630; http://finance.yahoo.com/news/avinger-provides-strategic-200100859.html
2. The Company expects to file a 510(k) application for Pantheris 3.0 during the third quarter of 2017; 20170701; 20170930; http://finance.yahoo.com/news/avinger-provides-strategic-200100859.html
3. 510(k) application for this Pantheris BTK device in the fourth quarter of 2017; 20171001; 20172131; http://finance.yahoo.com/news/avinger-provides-strategic-200100859.html

3) GNMX – Medgenics Inc
a. Buy at <~ $1.50
b. Sell at >~ $4.00
c. Catalysts:
1. Multiple trails to complete / Catalysts by EOY 2017; 20170321; 20171231; http://aevigenomics.com/c/pipeline/index.php

4) TEAR – TearLab Corp – Trading Below Cash
a. Buy at <~ $1.85
b. Sell at >~ $3.80
c. Catalysts:
1. Brazil registration being prepared with approval expected in 2017; 20170401; 20171231; https://www.tearlab.com/pdfs/Investor_Deck_April_12_2016.pdf&ved=0ahUKEwjBh7XJkIPTAhXDbxQKHamVCUkQFggfMAE&usg=AFQjCNEKRfW9rZ8OVqPr90z1BUdKJZogbw&sig2=wUP5_4hRdr5-LwiorihWxQ
2. New platform launch in 2017 will drive higher revenue and margins; 20170401; 20171231; https://www.tearlab.com/pdfs/Investor_Deck_April_12_2016.pdf&ved=0ahUKEwjBh7XJkIPTAhXDbxQKHamVCUkQFggfMAE&usg=AFQjCNEKRfW9rZ8OVqPr90z1BUdKJZogbw&sig2=wUP5_4hRdr5-LwiorihWxQ

5) EARS – Auris Medical Holding AG – Trading Below Cash
a. Buy at <~ $0.62
b. Sell at >~ $1.50
c. Catalysts:
1. Phase 3 HEALOS data due 2H 2017. Reported September, 2016 that enrollment had reached halfway. – AM-111 HEALOS – Acute inner ear hearing loss – Phase 3; 20170701; 20171231; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
2. data from first AM-111 Phase 3 trial expected in Q3; 20170701; 20170930;
3. Phase 3 ASSENT data due 1H 2018. – AM-111 ASSENT – Acute inner ear hearing loss – Phase 3; 20180101; 20180630; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
4. Phase 3 TACTT3 enrollment resumption announced January 26, 2017 with top-line results expected in early 2018. – AM-101 – TACTT3 – Acute inner ear tinnitus – Phase 3; 20180101; 20180331; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2227813

6) AVEO – AVEO Pharmaceuticals, Inc.
a. Buy at <~ $0.50
b. Sell at >~ $0.97
c. Catalysts:
1. Phase 3 enrollment to be completed June 2017. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20170601; 20170630; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868
2. initial results from the Opdivo combination TiNivo study in RCC in the first half of 2017; 20170401; 20170630; https://seekingalpha.com/instablog/44479986-leny-hettmansperger/4974435-aveo-59c-insiders-recently-purchased-almost-10m-share-lots-significant-catalysts-upside-ahead?uprof=45&isDirectRoadblock=true
3. Phase 1/2 initiation of dosing announced March 22, 2017. Phase 1 part of trial data due 1H 2017. – Tivozanib + Opdivo – Renal cell cancer (RCC) – Phase 1/2; 20170630; 20170630; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255714
4. Top-line data due 1Q 2018. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20180101; 20180331; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868
5. Futility analysis due mid-2017. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20170630; 20170930; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868

7) ONCS – OncoSec Medical Inc
a. Buy at <~ $1.10
b. Sell at >~ $1.95
c. Catalysts:
1. The PISCES (Anti-PD-1 IL-12 Stage III/IV Combination Electroporation Study) Phase 2b clinical trial is planned to initiate in the first half of 2017; 20170228; 20170630; http://www.prnewswire.com/news-releases/oncosec-granted-fda-fast-track-designation-for-immunopulse-il-12-for-the-treatment-of-metastatic-melanoma-following-progression-on-pembrolizumab-or-nivolumab-300413726.html

8) MICT – Micronet Enertec Technologies Inc
a. Buy at <~ $1.12
b. Sell at >~ $1.58

9) RTTR – Ritter Pharmaceuticals Inc
a. Buy at <~ $0.95
b. Sell at >~ $3.70
c. Catalysts:
1. end of phase 2 meeting with the company which is expected to take place in the third quarter of 2017; 20170701; 20170930; http://finance.yahoo.com/news/ritter-pharmaceuticals-inc-announces-end-140000803.html
2. initiation of phase 3 in the first half of 2018; 20180101; 20180630; http://finance.yahoo.com/news/ritter-pharmaceuticals-inc-announces-end-140000803.html

10) TCON – TRACON Pharmaceuticals Inc
a. Buy at <~ $3.60
b. Sell at >~ $7.00
c. Catalysts:
1. Phase 2 data of TRC105 and Nexavar for Hepatocellular carcinoma due 2017; 20170101; 20171231; http://ir.traconpharma.com/phoenix.zhtml?c=253885&p=irol-newsArticle&ID=2169453
2. Small molecule inhibitor of mutated and wild-type Androgen Receptor • Expect Phase 1/2 dosing in 1H 2017; 20170401; 20170630; http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MzczNTYwfENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=636270019327888891
3. PHASE 2 in GBM detailed data expected mid-2017; 20170401; 20170930; http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MzczNTYwfENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=636270019327888891

11) XENE – Xenon Pharmaceuticals Inc
a. Buy at <~ $3.65
b. Sell at >~ $7.50
c. Catalysts:
1. Genentech anticipates initiating a Phase 2 clinical trial in 2017 for the potential treatment of pain; 20170101; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
2. Phase 2b clinical trial of TV-45070 topline results expected in mid-2017.; 20170401; 20170930; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
3. Xenon expects to file an investigational new drug (IND) application in the fourth quarter of 2017; 20171001; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 04/17/2017 – 04/21/2017, and Why?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 04/24/2017 – 04/28/2017:

1) GALE – Galena Biopharma Inc – Trading Below Cash
a. Buy at < ~ $0.53
b. Sell at >~ $3.15

2) AVGR – Avinger Inc – Trading Below Cash
a. Buy at < ~ $0.50
b. Sell at >~ $1.50
c. Catalysts:
1. In-Stent Restenosis Trial final results are expected to be released by the end of June 2017; 20170601; 20170630; http://finance.yahoo.com/news/avinger-provides-strategic-200100859.html
2. The Company expects to file a 510(k) application for Pantheris 3.0 during the third quarter of 2017; 20170701; 20170930; http://finance.yahoo.com/news/avinger-provides-strategic-200100859.html
3. 510(k) application for this Pantheris BTK device in the fourth quarter of 2017; 20171001; 20172131; http://finance.yahoo.com/news/avinger-provides-strategic-200100859.html

3) ATEC – Alphatec Holdings Inc – Trading Below Cash
a. Buy at < ~ $1.96
b. Sell at >~ $5.80

4) GNMX – Medgenics Inc
a. Buy at < ~ $1.50
b. Sell at >~ $4.00
c. Catalysts:
1. Multiple trails to complete / Catalysts by EOY 2017; 20170321; 20171231; http://aevigenomics.com/c/pipeline/index.php

5) TEAR – TearLab Corp – Trading Below Cash
a. Buy at < ~ $1.85
b. Sell at >~ $3.80
c. Catalysts:
1. Brazil registration being prepared with approval expected in 2017; 20170401; 20171231; https://www.tearlab.com/pdfs/Investor_Deck_April_12_2016.pdf&ved=0ahUKEwjBh7XJkIPTAhXDbxQKHamVCUkQFggfMAE&usg=AFQjCNEKRfW9rZ8OVqPr90z1BUdKJZogbw&sig2=wUP5_4hRdr5-LwiorihWxQ
2. New platform launch in 2017 will drive higher revenue and margins; 20170401; 20171231; https://www.tearlab.com/pdfs/Investor_Deck_April_12_2016.pdf&ved=0ahUKEwjBh7XJkIPTAhXDbxQKHamVCUkQFggfMAE&usg=AFQjCNEKRfW9rZ8OVqPr90z1BUdKJZogbw&sig2=wUP5_4hRdr5-LwiorihWxQ

6) EARS – Auris Medical Holding AG – Trading Below Cash
a. Buy at < ~ $0.62
b. Sell at >~ $1.50
c. Catalysts:
1. Phase 3 HEALOS data due 2H 2017. Reported September, 2016 that enrollment had reached halfway. – AM-111 HEALOS – Acute inner ear hearing loss – Phase 3; 20170701; 20171231; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
2. data from first AM-111 Phase 3 trial expected in Q3; 20170701; 20170930;
3. Phase 3 ASSENT data due 1H 2018. – AM-111 ASSENT – Acute inner ear hearing loss – Phase 3; 20180101; 20180630; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
4. Phase 3 TACTT3 enrollment resumption announced January 26, 2017 with top-line results expected in early 2018. – AM-101 – TACTT3 – Acute inner ear tinnitus – Phase 3; 20180101; 20180331; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2227813

7) AVEO – AVEO Pharmaceuticals, Inc.
a. Buy at < ~ $0.50
b. Sell at >~ $0.97
c. Catalysts:
1. Phase 3 enrollment to be completed June 2017. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20170601; 20170630; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868
2. initial results from the Opdivo combination TiNivo study in RCC in the first half of 2017; 20170401; 20170630; https://seekingalpha.com/instablog/44479986-leny-hettmansperger/4974435-aveo-59c-insiders-recently-purchased-almost-10m-share-lots-significant-catalysts-upside-ahead?uprof=45&isDirectRoadblock=true
3. Phase 1/2 initiation of dosing announced March 22, 2017. Phase 1 part of trial data due 1H 2017. – Tivozanib + Opdivo – Renal cell cancer (RCC) – Phase 1/2; 20170630; 20170630; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255714
4. Top-line data due 1Q 2018. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20180101; 20180331; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868
5. Futility analysis due mid-2017. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20170630; 20170930; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868

8) ONCS – OncoSec Medical Inc
a. Buy at < ~ $1.10
b. Sell at >~ $1.95
c. Catalysts:
1. The PISCES (Anti-PD-1 IL-12 Stage III/IV Combination Electroporation Study) Phase 2b clinical trial is planned to initiate in the first half of 2017; 20170228; 20170630; http://www.prnewswire.com/news-releases/oncosec-granted-fda-fast-track-designation-for-immunopulse-il-12-for-the-treatment-of-metastatic-melanoma-following-progression-on-pembrolizumab-or-nivolumab-300413726.html

9) BDSI – BioDelivery Sciences International, Inc.
a. Buy at < ~ $1.55
b. Sell at >~ $2.15

10) QURE – Uniqure NV – Trading Below Cash
a. Buy at < ~ $5.15
b. Sell at >~ $8.30

11) RTTR – Ritter Pharmaceuticals Inc
a. Buy at < ~ $0.95
b. Sell at >~ $3.70
c. Catalysts:
1. end of phase 2 meeting with the company which is expected to take place in the third quarter of 2017; 20170701; 20170930; http://finance.yahoo.com/news/ritter-pharmaceuticals-inc-announces-end-140000803.html
2. initiation of phase 3 in the first half of 2018; 20180101; 20180630; http://finance.yahoo.com/news/ritter-pharmaceuticals-inc-announces-end-140000803.html

12) XENE – Xenon Pharmaceuticals Inc
a. Buy at < ~ $3.65
b. Sell at >~ $7.50
c. Catalysts:
1. Genentech anticipates initiating a Phase 2 clinical trial in 2017 for the potential treatment of pain; 20170101; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
2. Phase 2b clinical trial of TV-45070 topline results expected in mid-2017.; 20170401; 20170930; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
3. Xenon expects to file an investigational new drug (IND) application in the fourth quarter of 2017; 20171001; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 04/24/2017 - 04/28/2017, and Why?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowCash (#TBC) = $AVIR $DMTX $OPHT $PRTO $TNDM $TROV

#Bullish #Stocks currently #TradingBelowBook ( #TBB ) = $DMTX $NVGN $PRTO $TROV

#StockPicks #Stock #Market #Trades #Trading #TICKER

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 05/01/2017 – 05/05/2017:

1) GALE – Galena Biopharma Inc
a. Buy at < ~ $0.53
b. Sell at >~ $3.15
c. Catalysts:
1. Q1 2017 Galena Biopharma Inc Earnings Release (Estimated)
-; 20170508; 20170508; https://www.google.com/finance?q=GALE

2) AVGR – Avinger Inc – Trading Below Cash
a. Buy at < ~ $0.50
b. Sell at >~ $1.50
c. Catalysts:
1. In-Stent Restenosis Trial final results are expected to be released by the end of June 2017; 20170601; 20170630; http://finance.yahoo.com/news/avinger-provides-strategic-200100859.html
2. The Company expects to file a 510(k) application for Pantheris 3.0 during the third quarter of 2017; 20170701; 20170930; http://finance.yahoo.com/news/avinger-provides-strategic-200100859.html
3. 510(k) application for this Pantheris BTK device in the fourth quarter of 2017; 20171001; 20172131; http://finance.yahoo.com/news/avinger-provides-strategic-200100859.html

3) ATEC – Alphatec Holdings Inc – Trading Below Cash
a. Buy at < ~ $1.96
b. Sell at >~ $5.80

4) GNMX – Medgenics Inc
a. Buy at < ~ $1.30
b. Sell at >~ $4.00
c. Catalysts:
1. Multiple trails to complete / Catalysts by EOY 2017; 20170321; 20171231; http://aevigenomics.com/c/pipeline/index.php

5) TEAR – TearLab Corp – Trading Below Cash
a. Buy at < ~ $1.85
b. Sell at >~ $3.80
c. Catalysts:
1. Brazil registration being prepared with approval expected in 2017; 20170401; 20171231; https://www.tearlab.com/pdfs/Investor_Deck_April_12_2016.pdf&ved=0ahUKEwjBh7XJkIPTAhXDbxQKHamVCUkQFggfMAE&usg=AFQjCNEKRfW9rZ8OVqPr90z1BUdKJZogbw&sig2=wUP5_4hRdr5-LwiorihWxQ
2. New platform launch in 2017 will drive higher revenue and margins; 20170401; 20171231; https://www.tearlab.com/pdfs/Investor_Deck_April_12_2016.pdf&ved=0ahUKEwjBh7XJkIPTAhXDbxQKHamVCUkQFggfMAE&usg=AFQjCNEKRfW9rZ8OVqPr90z1BUdKJZogbw&sig2=wUP5_4hRdr5-LwiorihWxQ

6) EARS – Auris Medical Holding AG – Trading Below Cash
a. Buy at < ~ $0.62
b. Sell at >~ $1.50
c. Catalysts:
1. Phase 3 HEALOS data due 2H 2017. Reported September, 2016 that enrollment had reached halfway. – AM-111 HEALOS – Acute inner ear hearing loss – Phase 3; 20170701; 20171231; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
2. data from first AM-111 Phase 3 trial expected in Q3; 20170701; 20170930;
3. Phase 3 ASSENT data due 1H 2018. – AM-111 ASSENT – Acute inner ear hearing loss – Phase 3; 20180101; 20180630; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
4. Phase 3 TACTT3 enrollment resumption announced January 26, 2017 with top-line results expected in early 2018. – AM-101 – TACTT3 – Acute inner ear tinnitus – Phase 3; 20180101; 20180331; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2227813

7) AVEO – AVEO Pharmaceuticals, Inc.
a. Buy at < ~ $0.50
b. Sell at >~ $0.97
c. Catalysts:
1. Phase 3 enrollment to be completed June 2017. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20170601; 20170630; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868
2. initial results from the Opdivo combination TiNivo study in RCC in the first half of 2017; 20170401; 20170630; https://seekingalpha.com/instablog/44479986-leny-hettmansperger/4974435-aveo-59c-insiders-recently-purchased-almost-10m-share-lots-significant-catalysts-upside-ahead?uprof=45&isDirectRoadblock=true
3. Phase 1/2 initiation of dosing announced March 22, 2017. Phase 1 part of trial data due 1H 2017. – Tivozanib + Opdivo – Renal cell cancer (RCC) – Phase 1/2; 20170630; 20170630; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255714
4. Top-line data due 1Q 2018. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20180101; 20180331; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868
5. Futility analysis due mid-2017. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20170630; 20170930; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868

8) ONCS – OncoSec Medical Inc
a. Buy at < ~ $1.10
b. Sell at >~ $1.95
c. Catalysts:
1. The PISCES (Anti-PD-1 IL-12 Stage III/IV Combination Electroporation Study) Phase 2b clinical trial is planned to initiate in the first half of 2017; 20170228; 20170630; http://www.prnewswire.com/news-releases/oncosec-granted-fda-fast-track-designation-for-immunopulse-il-12-for-the-treatment-of-metastatic-melanoma-following-progression-on-pembrolizumab-or-nivolumab-300413726.html
2. Q3 2017 OncoSec Medical Inc Earnings Release (Estimated)
-; 20170607; 20170607; https://www.google.com/finance?q=ONCS

9) ONTX – Onconova Therapeutics Inc – Trading Below Cash
a. Buy at < ~ $2.00
b. Sell at >~ $3.45
c. Catalysts:
1. Q1 2017 Onconova Therapeutics Inc Earnings Release (Estimated)
-; 20170509; 20170509; https://www.google.com/finance?q=ONTX
2. Original Phase 3 trial did not meet endpoint in Feb 2014. However, following "subgroup analyses" and lack of current treatment options a further Phase 3 trial was initiated in December 2015. Interim analysis due 2H 2017. Enrollment to be completed 1Q 2018. – IV Rigosertib – INSPIRE – 2nd-line HR-MDS (high risk myelodysplastic syndromes) – Phase 3; 20170701; 20171231; https://www.sec.gov/Archives/edgar/data/1130598/000110465916156981/a16-17154_110q.htm

10) BDSI – BioDelivery Sciences International, Inc.
a. Buy at < ~ $1.55
b. Sell at >~ $2.15

11) QURE – Uniqure NV – Trading Below Cash
a. Buy at < ~ $4.91
b. Sell at >~ $8.30
c. Catalysts:
1. Uniqure NV at UBS Global Healthcare Conference; 20170522; 20170522; https://www.google.com/finance?q=QURE
2. Q1 2017 Uniqure NV Earnings Release (Estimated); 20170529; 20170529; https://www.google.com/finance?q=QURE

12) RTTR – Ritter Pharmaceuticals Inc
a. Buy at < ~ $0.76
b. Sell at >~ $3.70
c. Catalysts:
1. end of phase 2 meeting with the company which is expected to take place in the third quarter of 2017; 20170701; 20170930; http://finance.yahoo.com/news/ritter-pharmaceuticals-inc-announces-end-140000803.html
2. initiation of phase 3 in the first half of 2018; 20180101; 20180630; http://finance.yahoo.com/news/ritter-pharmaceuticals-inc-announces-end-140000803.html

13) XENE – Xenon Pharmaceuticals Inc
a. Buy at < ~ $3.65
b. Sell at >~ $7.50
c. Catalysts:
1. Phase 2b clinical trial of TV-45070 topline results expected in mid-2017.; 20170401; 20170930; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
2. Genentech anticipates initiating a Phase 2 clinical trial in 2017 for the potential treatment of pain; 20170101; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
3. Xenon expects to file an investigational new drug (IND) application in the fourth quarter of 2017; 20171001; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
4. Q1 2017 Xenon Pharmaceuticals Inc Earnings Release (Estimated)
-; 20170508; 20170508; https://www.google.com/finance?q=XENE

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 05/01/2017 - 05/05/2017, and Why?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 05/08/2017 – 05/12/2017:

1) GALE – Galena Biopharma Inc
a. Buy at < ~ $0.53
b. Sell at >~ $3.15
c. Catalysts:
1. Q1 2017 Galena Biopharma Inc Earnings Release (Estimated)
-; 20170508; 20170508; https://www.google.com/finance?q=GALE

2) AVGR – Avinger Inc – Trading Below Cash
a. Buy at < ~ $0.46
b. Sell at >~ $1.50
c. Catalysts:
1. In-Stent Restenosis Trial final results are expected to be released by the end of June 2017; 20170601; 20170630; http://finance.yahoo.com/news/avinger-provides-strategic-200100859.html
2. The Company expects to file a 510(k) application for Pantheris 3.0 during the third quarter of 2017; 20170701; 20170930; http://finance.yahoo.com/news/avinger-provides-strategic-200100859.html
3. 510(k) application for this Pantheris BTK device in the fourth quarter of 2017; 20171001; 20172131; http://finance.yahoo.com/news/avinger-provides-strategic-200100859.html

3) ATEC – Alphatec Holdings Inc – Trading Below Cash
a. Buy at < ~ $1.96
b. Sell at >~ $5.80

4) GNMX – Medgenics Inc
a. Buy at < ~ $1.30
b. Sell at >~ $4.00
c. Catalysts:
1. Multiple trails to complete / Catalysts by EOY 2017; 20170321; 20171231; http://aevigenomics.com/c/pipeline/index.php

5) TEAR – TearLab Corp – Trading Below Cash
a. Buy at < ~ $1.85
b. Sell at >~ $3.80
c. Catalysts:
1. Brazil registration being prepared with approval expected in 2017; 20170401; 20171231; https://www.tearlab.com/pdfs/Investor_Deck_April_12_2016.pdf&ved=0ahUKEwjBh7XJkIPTAhXDbxQKHamVCUkQFggfMAE&usg=AFQjCNEKRfW9rZ8OVqPr90z1BUdKJZogbw&sig2=wUP5_4hRdr5-LwiorihWxQ
2. New platform launch in 2017 will drive higher revenue and margins; 20170401; 20171231; https://www.tearlab.com/pdfs/Investor_Deck_April_12_2016.pdf&ved=0ahUKEwjBh7XJkIPTAhXDbxQKHamVCUkQFggfMAE&usg=AFQjCNEKRfW9rZ8OVqPr90z1BUdKJZogbw&sig2=wUP5_4hRdr5-LwiorihWxQ

6) EARS – Auris Medical Holding AG – Trading Below Cash
a. Buy at < ~ $0.62
b. Sell at >~ $1.50
c. Catalysts:
1. Phase 3 HEALOS data due 2H 2017. Reported September, 2016 that enrollment had reached halfway. – AM-111 HEALOS – Acute inner ear hearing loss – Phase 3; 20170701; 20171231; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
2. data from first AM-111 Phase 3 trial expected in Q3; 20170701; 20170930;
3. Phase 3 ASSENT data due 1H 2018. – AM-111 ASSENT – Acute inner ear hearing loss – Phase 3; 20180101; 20180630; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
4. Phase 3 TACTT3 enrollment resumption announced January 26, 2017 with top-line results expected in early 2018. – AM-101 – TACTT3 – Acute inner ear tinnitus – Phase 3; 20180101; 20180331; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2227813

7) AVEO – AVEO Pharmaceuticals, Inc.
a. Buy at < ~ $0.50
b. Sell at >~ $0.97
c. Catalysts:
1. Phase 3 enrollment to be completed June 2017. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20170601; 20170630; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868
2. initial results from the Opdivo combination TiNivo study in RCC in the first half of 2017; 20170401; 20170630; https://seekingalpha.com/instablog/44479986-leny-hettmansperger/4974435-aveo-59c-insiders-recently-purchased-almost-10m-share-lots-significant-catalysts-upside-ahead?uprof=45&isDirectRoadblock=true
3. Phase 1/2 initiation of dosing announced March 22, 2017. Phase 1 part of trial data due 1H 2017. – Tivozanib + Opdivo – Renal cell cancer (RCC) – Phase 1/2; 20170630; 20170630; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255714
4. Top-line data due 1Q 2018. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20180101; 20180331; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868
5. Futility analysis due mid-2017. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20170630; 20170930; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868

8) ONCS – OncoSec Medical Inc
a. Buy at < ~ $1.10
b. Sell at >~ $1.95
c. Catalysts:
1. The PISCES (Anti-PD-1 IL-12 Stage III/IV Combination Electroporation Study) Phase 2b clinical trial is planned to initiate in the first half of 2017; 20170228; 20170630; http://www.prnewswire.com/news-releases/oncosec-granted-fda-fast-track-designation-for-immunopulse-il-12-for-the-treatment-of-metastatic-melanoma-following-progression-on-pembrolizumab-or-nivolumab-300413726.html
2. Q3 2017 OncoSec Medical Inc Earnings Release (Estimated)
-; 20170607; 20170607; https://www.google.com/finance?q=ONCS

9) ONTX – Onconova Therapeutics Inc – Trading Below Cash
a. Buy at < ~ $2.00
b. Sell at >~ $3.45
c. Catalysts:
1. Q1 2017 Onconova Therapeutics Inc Earnings Release (Estimated)
-; 20170509; 20170509; https://www.google.com/finance?q=ONTX
2. Original Phase 3 trial did not meet endpoint in Feb 2014. However, following "subgroup analyses" and lack of current treatment options a further Phase 3 trial was initiated in December 2015. Interim analysis due 2H 2017. Enrollment to be completed 1Q 2018. – IV Rigosertib – INSPIRE – 2nd-line HR-MDS (high risk myelodysplastic syndromes) – Phase 3; 20170701; 20171231; https://www.sec.gov/Archives/edgar/data/1130598/000110465916156981/a16-17154_110q.htm

10) RXII – RXi Pharmaceuticals Corp
a. Buy at < ~ $0.58
b. Sell at >~ $2.36
c. Catalysts:
1. Phase 2 first cohort data due 2Q 2017. Full data due 2H 2017. – Samcyprone – RXI-SCP-1502 – Cutaneous warts – Phase 2; 20170401; 20170630; http://investors.rxipharma.com/file/Index?KeyFile=37076476
2. Phase 2 final readout due mid 2017. – RXI-109-1402 – Connective tissue growth factor ( – Phase 2; 20170601; 20170731; http://investors.rxipharma.com/file/Index?KeyFile=37076476
3. Phase 2 enrollment to be completed early 2017. Safety data readout due 2H2017. – RXI-109-1501 – Retinal scarring – Phase 1/2; 20170701; 20171231; http://investors.rxipharma.com/file/Index?KeyFile=37076476

11) BDSI – BioDelivery Sciences International, Inc.
a. Buy at < ~ $1.55
b. Sell at >~ $2.15

12) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.17
b. Sell at >~ $2.45

13) QURE – Uniqure NV – Trading Below Cash
a. Buy at < ~ $4.91
b. Sell at >~ $8.30
c. Catalysts:
1. Uniqure NV at UBS Global Healthcare Conference; 20170522; 20170522; https://www.google.com/finance?q=QURE
2. Q1 2017 Uniqure NV Earnings Release (Estimated); 20170529; 20170529; https://www.google.com/finance?q=QURE

14) XENE – Xenon Pharmaceuticals Inc
a. Buy at < ~ $3.65
b. Sell at >~ $7.50
c. Catalysts:
1. Phase 2b clinical trial of TV-45070 topline results expected in mid-2017.; 20170401; 20170930; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
2. Genentech anticipates initiating a Phase 2 clinical trial in 2017 for the potential treatment of pain; 20170101; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
3. Xenon expects to file an investigational new drug (IND) application in the fourth quarter of 2017; 20171001; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
4. Q1 2017 Xenon Pharmaceuticals Inc Earnings Release (Estimated)
-; 20170508; 20170508; https://www.google.com/finance?q=XENE

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 05/08/2017 - 05/12/2017, and Why?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowCash (#TBC) as of 05/05/2017 include:

1. $AVIR – Aviragen Therapeutics Inc :
   1. Cash/sh = $1.27
2. $DMTX – Dimension Therapeutics Inc :
   1. Cash/sh = $3.12
3. $OPHT – Ophthotech Corp :
   1. Cash/sh = $7.94
4. $PRTO – Proteon Therapeutics Inc :
   1. Cash/sh = $2.56
5. $TNDM – Tandem Diabetes Care Inc :
   1. Cash/sh = $1.06
6. $VICL – Vical Incorporated :
   1. Cash/sh = $3.45

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

#StockPicks #Stock #Market #Trading

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook ( #TBB ) as of 05/05/2017 include:

1. $AVIR – Aviragen Therapeutics Inc :
   1. Book/sh = $0.72
2. $DMTX – Dimension Therapeutics Inc :
   1. Book/sh = $2.40
3. $FLKS – Flex Pharma Inc :
   1. Book/sh = $3.57
4. $KTOV – Kitov Pharmaceuticals Holdings Ltd :
   1. Book/sh = $1.80
5. $NVGN – Novogen Limited (ADR) :
   1. Book/sh = $1.31
6. $OREX – Orexigen Therapeutics, Inc. :
   1. Book/sh = $5.03
7. $PRTO – Proteon Therapeutics Inc :
   1. Book/sh = $2.32
8. $TNXP – Tonix Pharmaceuticals Holding Corp. :
   1. Book/sh = $7.04
9. $TOPS – TOP SHIPS Inc :
   1. Book/sh = $9.83
10. $VICL – Vical Incorporated :
    1. Book/sh = $4.05

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

#StockPicks #Stock #Market #Trading

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 05/15/2017 – 05/19/2017:

1) ATEC – Alphatec Holdings Inc – Trading Below Cash
a. Buy at < ~ $1.96
b. Sell at >~ $5.80

2) GNMX – Medgenics Inc
a. Buy at < ~ $1.30
b. Sell at >~ $4.00
c. Catalysts:
1. Multiple trails to complete / Catalysts by EOY 2017; 20170321; 20171231; http://aevigenomics.com/c/pipeline/index.php

3) CTRV – ContraVir Pharmaceuticals Inc
a. Buy at < ~ $0.62
b. Sell at >~ $1.25
c. Catalysts:
1. Phase 2, Multiple Ascending Dose Proof of Concept Study; 20170601; 20170930; https://clinicaltrials.gov/ct2/show/NCT02710604?term=CONTRAVIR&rank=1
2. A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia; 20171231; 20181231; https://clinicaltrials.gov/ct2/show/NCT02412917?term=CONTRAVIR&rank=3

4) EARS – Auris Medical Holding AG – Trading Below Cash
a. Buy at < ~ $0.62
b. Sell at >~ $1.50
c. Catalysts:
1. Phase 3 HEALOS data due 2H 2017. Reported September, 2016 that enrollment had reached halfway. – AM-111 HEALOS – Acute inner ear hearing loss – Phase 3; 20170701; 20171231; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
2. data from first AM-111 Phase 3 trial expected in Q3; 20170701; 20170930;
3. Phase 3 ASSENT data due 1H 2018. – AM-111 ASSENT – Acute inner ear hearing loss – Phase 3; 20180101; 20180630; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
4. Phase 3 TACTT3 enrollment resumption announced January 26, 2017 with top-line results expected in early 2018. – AM-101 – TACTT3 – Acute inner ear tinnitus – Phase 3; 20180101; 20180331; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2227813

5) ONTX – Onconova Therapeutics Inc – Trading Below Cash
a. Buy at < ~ $2.00
b. Sell at >~ $3.45
c. Catalysts:
1. Original Phase 3 trial did not meet endpoint in Feb 2014. However, following “subgroup analyses” and lack of current treatment options a further Phase 3 trial was initiated in December 2015. Interim analysis due 2H 2017. Enrollment to be completed 1Q 2018. – IV Rigosertib – INSPIRE – 2nd-line HR-MDS (high risk myelodysplastic syndromes) – Phase 3; 20170701; 20171231; https://www.sec.gov/Archives/edgar/data/1130598/000110465916156981/a16-17154_110q.htm

6) GALE – Galena Biopharma Inc
a. Buy at < ~ $0.53
b. Sell at >~ $0.79
c. Catalysts:
1. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b DSMB expects to perform the interim efficacy analysis near the end of 2017; 20171115; 20171231; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
2. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b Completion of enrollment is expected in the second quarter of 2017; 20170515; 20170630; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
3. Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (HER3+); 20191231; 20201231; https://clinicaltrials.gov/ct2/show/NCT02297698?term=neuvax&rank=1
4. Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer; 20190301; 20190331; https://clinicaltrials.gov/ct2/show/NCT02636582?term=NCT02636582&rank=1

7) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.17
b. Sell at >~ $2.45

8) SRNE – Sorrento Therapeutics Inc – Trading Below Cash
a. Buy at < ~ $1.55
b. Sell at >~ $2.10
c. Catalysts:
1. STI-001 regulatory pathway and discussions with FDA in 2017; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
2. Potential LA Cell (iTAb) partnership; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
3. Biosimilars Erbitux 1.2Billion Remicade 6.6Billion Xolair 0.8Billion – combined huge market potential; FDA in 1H’17; 20170101; 20170630; https://twitter.com/DrSManian
4. STI-A1014 PD-L1 mAb IND filing in 2017 in CN; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
5. IND filing for c-MET ADC expected in 2017 / 2018; 20170701; 20181231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
6. AntiPD1 Antibody – big licensing deal with Servier – will be in clinic 2H 2017; 20170701; 20171231; https://twitter.com/DrSManian
7. 3 clinical programs in 2017 w/ promising human & in vivo proof-of-concept data; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 05/15/2017 – 05/19/2017, and Why?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowCash (#TBC) as of 05/12/2017 include

1. $AVGR – Avinger Inc :
   1. Cash/sh = $1.37
2. $AVIR – Aviragen Therapeutics Inc :
   1. Cash/sh = $1.27
3. $DMTX – Dimension Therapeutics Inc :
   1. Cash/sh = $3.12
4. $OPHT – Ophthotech Corp :
   1. Cash/sh = $7.94
5. $OREX – Orexigen Therapeutics, Inc. :
   1. Cash/sh = $5.19
6. $QURE – Uniqure NV :
   1. Cash/sh = $5.37
7. $TEAR – TearLab Corp :
   1. Cash/sh = $2.77
8. $TNDM – Tandem Diabetes Care Inc :
   1. Cash/sh = $1.06
9. $VICL – Vical Incorporated :
   1. Cash/sh = $3.45

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook ( #TBB ) as of 05/12/2017 include:

1. $AVIR – Aviragen Therapeutics Inc :
   1. Book/sh = $0.72
2. $FLKS – Flex Pharma Inc :
   1. Book/sh = $3.57
3. $KTOV – Kitov Pharmaceuticals Holdings Ltd :
   1. Book/sh = $1.80
4. $NVGN – Novogen Limited (ADR) :
   1. Book/sh = $1.31
5. $OREX – Orexigen Therapeutics, Inc. :
   1. Book/sh = $5.03
6. $RXII – RXi Pharmaceuticals Corp :
   1. Book/sh = $1.00
7. $TNXP – Tonix Pharmaceuticals Holding Corp. :
   1. Book/sh = $7.04
8. $TOPS – TOP SHIPS Inc :
   1. Book/sh = $9.83
9. $VICL – Vical Incorporated :
   1. Book/sh = $4.05

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 06/05/2017 – 06/09/2017:

1) ATEC – Alphatec Holdings Inc – Trading Below Cash
a. Buy at < ~ $1.77
b. Sell at >~ $5.80

2) CTRV – ContraVir Pharmaceuticals Inc
a. Buy at < ~ $0.60
b. Sell at >~ $1.25
c. Catalysts:
1. Phase 2, Multiple Ascending Dose Proof of Concept Study; 20170601; 20170930; https://clinicaltrials.gov/ct2/show/NCT02710604?term=CONTRAVIR&rank=1
2. A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia; 20171231; 20181231; https://clinicaltrials.gov/ct2/show/NCT02412917?term=CONTRAVIR&rank=3

3) EARS – Auris Medical Holding AG – Trading Below Cash
a. Buy at < ~ $0.60
b. Sell at >~ $1.50
c. Catalysts:
1. Phase 3 HEALOS data due 2H 2017. Reported September, 2016 that enrollment had reached halfway. – AM-111 HEALOS – Acute inner ear hearing loss – Phase 3; 20170701; 20171231; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
2. data from first AM-111 Phase 3 trial expected in Q3; 20170701; 20170930;
3. Phase 3 ASSENT data due 1H 2018. – AM-111 ASSENT – Acute inner ear hearing loss – Phase 3; 20180101; 20180630; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
4. Phase 3 TACTT3 enrollment resumption announced January 26, 2017 with top-line results expected in early 2018. – AM-101 – TACTT3 – Acute inner ear tinnitus – Phase 3; 20180101; 20180331; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2227813

4) ROKA – Roka Bioscience Inc – Trading Below Cash
a. Buy at < ~ $2.52
b. Sell at >~ $4.66

5) SCYX – SCYNEXIS Inc – Trading Below Cash
a. Buy at < ~ $1.56
b. Sell at >~ $2.93
c. Catalysts:
1. Q2 – Initiate ph 3 Oral for treatment of refractory invasive fungal infections (rIFI) intolerant to standard antifungal agents (FURI study); 20170401; 20170630; https://twitter.com/crewdog58/status/871138582706180098
2. Open-Label Study to Evaluate Efficacy and Safety of SCY-078 in Patients With Refractory or Intolerant Fungal Diseases (FURI); expected to start patient enrollment in Q2, 2017; 20170401; 20170630; https://seekingalpha.com/article/4073253-scynexis-another-buy-opportunity-recent-pullback
3. Open-Label Study to Evaluate Efficacy and Safety of SCY-078 in Patients With Refractory or Intolerant Fungal Diseases (FURI); 20190901; 20191231; https://clinicaltrials.gov/ct2/show/NCT03059992?term=SCYNEXIS&rank=3
4. Mid-2017 – Submission of IV data analysis to FDA; 20170601; 20171231; https://twitter.com/crewdog58/status/871138614591270912

6) GALE – Galena Biopharma Inc – Trading Below Cash
a. Buy at < ~ $0.53
b. Sell at >~ $0.79
c. Catalysts:
1. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b DSMB expects to perform the interim efficacy analysis near the end of 2017; 20171115; 20171231; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
2. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b Completion of enrollment is expected in the second quarter of 2017; 20170515; 20170630; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
3. Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (HER3+); 20191231; 20201231; https://clinicaltrials.gov/ct2/show/NCT02297698?term=neuvax&rank=1
4. Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer; 20190301; 20190331; https://clinicaltrials.gov/ct2/show/NCT02636582?term=NCT02636582&rank=1

7) ECYT – Endocyte, Inc. – Trading Below Cash
a. Buy at < ~ $1.80
b. Sell at >~ $3.22
c. Catalysts:
1. Phase 1 data for EC1456 and EC1169; 2016; ;
2. Endocyte to Announce Updated Data on EC1456 and EC1169 at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting; 20170605; 20170605; https://seekingalpha.com/pr/16845518-endocyte-announce-updated-data-ec1456-ec1169-2017-american-society-clinical-oncology-asco

8) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.11
b. Sell at >~ $2.45

9) SRNE – Sorrento Therapeutics Inc
a. Buy at < ~ $1.50
b. Sell at >~ $2.10
c. Catalysts:
1. STI-001 regulatory pathway and discussions with FDA in 2017; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
2. Potential LA Cell (iTAb) partnership; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
3. Biosimilars Erbitux 1.2Billion Remicade 6.6Billion Xolair 0.8Billion – combined huge market potential; FDA in 1H’17; 20170101; 20170630; https://twitter.com/DrSManian
4. STI-A1014 PD-L1 mAb IND filing in 2017 in CN; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
5. IND filing for c-MET ADC expected in 2017 / 2018; 20170701; 20181231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
6. AntiPD1 Antibody – big licensing deal with Servier – will be in clinic 2H 2017; 20170701; 20171231; https://twitter.com/DrSManian
7. 3 clinical programs in 2017 w/ promising human & in vivo proof-of-concept data; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 06/05/2017 – 06/09/2017, and Why?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowCash (#TBC) as of 06/02/2017 include

1. $AVIR – Aviragen Therapeutics Inc :
   1. Cash/sh = $1.27
2. $DMTX – Dimension Therapeutics Inc :
   1. Cash/sh = $2.15
3. $OPHT – Ophthotech Corp :
   1. Cash/sh = $7.94
4. $OREX – Orexigen Therapeutics, Inc. :
   1. Cash/sh = $5.82
5. $PRTO – Proteon Therapeutics Inc :
   1. Cash/sh = $2.56
6. $TCON – TRACON Pharmaceuticals Inc :
   1. Cash/sh = $2.78
7. $TEAR – TearLab Corp :
   1. Cash/sh = $2.77
8. $TNDM – Tandem Diabetes Care Inc :
   1. Cash/sh = $1.06

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook ( #TBB ) as of 06/02/2017 include:

1. $AVIR – Aviragen Therapeutics Inc :
   1. Book/sh = $0.72
2. $DMTX – Dimension Therapeutics Inc :
   1. Book/sh = $1.90
3. $FLKS – Flex Pharma Inc :
   1. Book/sh = $3.57
4. $NVGN – Novogen Limited (ADR) :
   1. Book/sh = $1.31
5. $PRTO – Proteon Therapeutics Inc :
   1. Book/sh = $1.98
6. $RXII – RXi Pharmaceuticals Corp :
   1. Book/sh = $1.00
7. $TNXP – Tonix Pharmaceuticals Holding Corp. :
   1. Book/sh = $7.04
8. $TOPS – TOP SHIPS Inc :
   1. Book/sh = $196.63

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 06/12/2017 – 06/16/2017:

1) ATEC – Alphatec Holdings Inc – Trading Below Cash
a. Buy at < ~ $1.77
b. Sell at >~ $5.80

2) CTRV – ContraVir Pharmaceuticals Inc
a. Buy at < ~ $0.60
b. Sell at >~ $1.25
c. Catalysts:
1. Phase 2, Multiple Ascending Dose Proof of Concept Study; 20170601; 20170930; https://clinicaltrials.gov/ct2/show/NCT02710604?term=CONTRAVIR&rank=1
2. A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia; 20171231; 20181231; https://clinicaltrials.gov/ct2/show/NCT02412917?term=CONTRAVIR&rank=3

3) ROKA – Roka Bioscience Inc – Trading Below Cash
a. Buy at < ~ $2.52
b. Sell at >~ $4.66

4) OVAS – OvaScience Inc – Trading Below Cash
a. Buy at < ~ $1.25
b. Sell at >~ $2.00
c. Catalysts:
1. @cutterend Mar. 21 at 10:45 PM $OVAS FDA meeting first half of 2017; 20170101; 20170630; http://stocktwits.com/cutterend?utm_campaign=widget&utm_medium=widget&utm_source=finviz.com
2. Q2 2017 OvaScience Inc Earnings Release (Estimated)
-; 20170802; 20170802; https://www.google.com/finance?q=OVAS

5) SCYX – SCYNEXIS Inc – Trading Below Cash
a. Buy at < ~ $1.56
b. Sell at >~ $2.93
c. Catalysts:
1. Open-Label Study to Evaluate Efficacy and Safety of SCY-078 in Patients With Refractory or Intolerant Fungal Diseases (FURI); expected to start patient enrollment in Q2, 2017; 20170401; 20170630; https://seekingalpha.com/article/4073253-scynexis-another-buy-opportunity-recent-pullback
2. Q2 – Initiate ph 3 Oral for treatment of refractory invasive fungal infections (rIFI) intolerant to standard antifungal agents (FURI study); 20170401; 20170630; https://twitter.com/crewdog58/status/871138582706180098
3. Mid-2017 – Submission of IV data analysis to FDA; 20170601; 20171231; https://twitter.com/crewdog58/status/871138614591270912
4. Open-Label Study to Evaluate Efficacy and Safety of SCY-078 in Patients With Refractory or Intolerant Fungal Diseases (FURI); 20190901; 20191231; https://clinicaltrials.gov/ct2/show/NCT03059992?term=SCYNEXIS&rank=3
5. Q2 2017 SCYNEXIS Inc Earnings Release (Estimated)
-; 20170807; 20170807; https://www.google.com/finance?q=SCYX

6) GALE – Galena Biopharma Inc – Trading Below Cash
a. Buy at < ~ $0.53
b. Sell at >~ $0.79
c. Catalysts:
1. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b DSMB expects to perform the interim efficacy analysis near the end of 2017; 20171115; 20171231; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
2. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b Completion of enrollment is expected in the second quarter of 2017; 20170515; 20170630; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
3. Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (HER3+); 20191231; 20201231; https://clinicaltrials.gov/ct2/show/NCT02297698?term=neuvax&rank=1
4. Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer; 20190301; 20190331; https://clinicaltrials.gov/ct2/show/NCT02636582?term=NCT02636582&rank=1

7) ECYT – Endocyte, Inc. – Trading Below Cash
a. Buy at < ~ $1.50
b. Sell at >~ $3.22
c. Catalysts:
1. Phase 1 data for EC1456 and EC1169; 2016; ;

8) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.11
b. Sell at >~ $2.45

9) SRNE – Sorrento Therapeutics Inc
a. Buy at < ~ $1.50
b. Sell at >~ $2.10
c. Catalysts:
1. STI-001 regulatory pathway and discussions with FDA in 2017; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
2. Potential LA Cell (iTAb) partnership; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
3. Biosimilars Erbitux 1.2Billion Remicade 6.6Billion Xolair 0.8Billion – combined huge market potential; FDA in 1H’17; 20170101; 20170630; https://twitter.com/DrSManian
4. STI-A1014 PD-L1 mAb IND filing in 2017 in CN; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
5. IND filing for c-MET ADC expected in 2017 / 2018; 20170701; 20181231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
6. AntiPD1 Antibody – big licensing deal with Servier – will be in clinic 2H 2017; 20170701; 20171231; https://twitter.com/DrSManian
7. 3 clinical programs in 2017 w/ promising human & in vivo proof-of-concept data; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf

10) ONTX – Onconova Therapeutics Inc
a. Buy at < ~ $1.78
b. Sell at >~ $2.14
c. Catalysts:
1. Original Phase 3 trial did not meet endpoint in Feb 2014. However, following “subgroup analyses” and lack of current treatment options a further Phase 3 trial was initiated in December 2015. Interim analysis due 2H 2017. Enrollment to be completed 1Q 2018. – IV Rigosertib – INSPIRE – 2nd-line HR-MDS (high risk myelodysplastic syndromes) – Phase 3; 20170701; 20171231; https://www.sec.gov/Archives/edgar/data/1130598/000110465916156981/a16-17154_110q.htm

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 06/12/2017 – 06/16/2017, and Why?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowCash (#TBC) as of 06/09/2017 include

1. $ADHD – Alcobra Ltd :
   1. Cash/sh = $1.81
2. $AVIR – Aviragen Therapeutics Inc :
   1. Cash/sh = $1.27
3. $DMTX – Dimension Therapeutics Inc :
   1. Cash/sh = $2.15
4. $EARS – Auris Medical Holding AG :
   1. Cash/sh = $1
5. $OPHT – Ophthotech Corp :
   1. Cash/sh = $7.94
6. $OREX – Orexigen Therapeutics, Inc. :
   1. Cash/sh = $5.82
7. $PRTO – Proteon Therapeutics Inc :
   1. Cash/sh = $2.56
8. $TCON – TRACON Pharmaceuticals Inc :
   1. Cash/sh = $2.78
9. $TEAR – TearLab Corp :
   1. Cash/sh = $2.77
10. $TNDM – Tandem Diabetes Care Inc :
    1. Cash/sh = $1.06

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook ( #TBB ) as of 06/09/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Book/sh = $1.71
2. $AVIR – Aviragen Therapeutics Inc :
   1. Book/sh = $0.72
3. $DMTX – Dimension Therapeutics Inc :
   1. Book/sh = $1.90
4. $FLKS – Flex Pharma Inc :
   1. Book/sh = $3.57
5. $KTOV – Kitov Pharmaceuticals Holdings Ltd :
   1. Book/sh = $1.80
6. $NVGN – Novogen Limited (ADR) :
   1. Book/sh = $1.31
7. $PRTO – Proteon Therapeutics Inc :
   1. Book/sh = $1.98
8. $RXII – RXi Pharmaceuticals Corp :
   1. Book/sh = $1.00
9. $TNXP – Tonix Pharmaceuticals Holding Corp. :
   1. Book/sh = $7.04
10. $TOPS – TOP SHIPS Inc :
    1. Book/sh = $196.63

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 06/19/2017 – 06/23/2017:

1) ATEC – Alphatec Holdings Inc – Trading Below Cash
a. Buy at < ~ $1.77
b. Sell at >~ $5.80

2) CTRV – ContraVir Pharmaceuticals Inc
a. Buy at < ~ $0.60
b. Sell at >~ $1.25
c. Catalysts:
1. Phase 2, Multiple Ascending Dose Proof of Concept Study; 20170601; 20170930; https://clinicaltrials.gov/ct2/show/NCT02710604?term=CONTRAVIR&rank=1
2. A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia; 20171231; 20181231; https://clinicaltrials.gov/ct2/show/NCT02412917?term=CONTRAVIR&rank=3

3) ROKA – Roka Bioscience Inc – Trading Below Cash
a. Buy at < ~ $2.52
b. Sell at >~ $4.66

4) OVAS – OvaScience Inc – Trading Below Cash
a. Buy at < ~ $1.25
b. Sell at >~ $2.00
c. Catalysts:
1. @cutterend Mar. 21 at 10:45 PM $OVAS FDA meeting first half of 2017; 20170101; 20170630; http://stocktwits.com/cutterend?utm_campaign=widget&utm_medium=widget&utm_source=finviz.com
2. Q2 2017 OvaScience Inc Earnings Release (Estimated)
-; 20170802; 20170802; https://www.google.com/finance?q=OVAS

5) SCYX – SCYNEXIS Inc – Trading Below Cash
a. Buy at < ~ $1.56
b. Sell at >~ $2.93
c. Catalysts:
1. Q2 – Initiate ph 3 Oral for treatment of refractory invasive fungal infections (rIFI) intolerant to standard antifungal agents (FURI study); 20170401; 20170630; https://twitter.com/crewdog58/status/871138582706180098
2. Open-Label Study to Evaluate Efficacy and Safety of SCY-078 in Patients With Refractory or Intolerant Fungal Diseases (FURI); expected to start patient enrollment in Q2, 2017; 20170401; 20170630; https://seekingalpha.com/article/4073253-scynexis-another-buy-opportunity-recent-pullback
3. Mid-2017 – Submission of IV data analysis to FDA; 20170601; 20171231; https://twitter.com/crewdog58/status/871138614591270912
4. Open-Label Study to Evaluate Efficacy and Safety of SCY-078 in Patients With Refractory or Intolerant Fungal Diseases (FURI); 20190901; 20191231; https://clinicaltrials.gov/ct2/show/NCT03059992?term=SCYNEXIS&rank=3
5. Q2 2017 SCYNEXIS Inc Earnings Release (Estimated)
-; 20170807; 20170807; https://www.google.com/finance?q=SCYX

6) GALE – Galena Biopharma Inc – Trading Below Cash
a. Buy at < ~ $0.53
b. Sell at >~ $0.79
c. Catalysts:
1. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b DSMB expects to perform the interim efficacy analysis near the end of 2017; 20171115; 20171231; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
2. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b Completion of enrollment is expected in the second quarter of 2017; 20170515; 20170630; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
3. Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (HER3+); 20191231; 20201231; https://clinicaltrials.gov/ct2/show/NCT02297698?term=neuvax&rank=1
4. Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer; 20190301; 20190331; https://clinicaltrials.gov/ct2/show/NCT02636582?term=NCT02636582&rank=1

7) ECYT – Endocyte, Inc. – Trading Below Cash
a. Buy at < ~ $1.50
b. Sell at >~ $3.22
c. Catalysts:
1. Phase 1 data for EC1456 and EC1169; 2016; ;

8) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.11
b. Sell at >~ $2.45

9) ONTX – Onconova Therapeutics Inc
a. Buy at < ~ $1.78
b. Sell at >~ $2.14
c. Catalysts:
1. Original Phase 3 trial did not meet endpoint in Feb 2014. However, following “subgroup analyses” and lack of current treatment options a further Phase 3 trial was initiated in December 2015. Interim analysis due 2H 2017. Enrollment to be completed 1Q 2018. – IV Rigosertib – INSPIRE – 2nd-line HR-MDS (high risk myelodysplastic syndromes) – Phase 3; 20170701; 20171231; https://www.sec.gov/Archives/edgar/data/1130598/000110465916156981/a16-17154_110q.htm

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 06/19/2017 – 06/23/2017, and Why?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 06/26/2017 – 06/30/2017:

1) ATEC – Alphatec Holdings Inc – Trading Below Cash
a. Buy at < ~ $1.77
b. Sell at >~ $5.80

2) DGLY – Digital Ally, Inc.
a. Buy at < ~ $3.45
b. Sell at >~ $6.50

3) EARS – Auris Medical Holding AG – Trading Below Cash
a. Buy at < ~ $0.60
b. Sell at >~ $1.50
c. Catalysts:
1. Phase 3 HEALOS data due 2H 2017. Reported September, 2016 that enrollment had reached halfway. – AM-111 HEALOS – Acute inner ear hearing loss – Phase 3; 20170701; 20171231; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
2. data from first AM-111 Phase 3 trial expected in Q3; 20170701; 20170930;
3. Phase 3 ASSENT data due 1H 2018. – AM-111 ASSENT – Acute inner ear hearing loss – Phase 3; 20180101; 20180630; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
4. Phase 3 TACTT3 enrollment resumption announced January 26, 2017 with top-line results expected in early 2018. – AM-101 – TACTT3 – Acute inner ear tinnitus – Phase 3; 20180101; 20180331; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2227813

4) UNXL – Uni-Pixel Inc
a. Buy at < ~ $0.35
b. Sell at >~ $0.60

5) GALE – Galena Biopharma Inc – Trading Below Cash
a. Buy at < ~ $0.53
b. Sell at >~ $0.79
c. Catalysts:
1. Q2 2017 Galena Biopharma Inc Earnings Release (Estimated)
-; 20170807; 20170807; https://www.google.com/finance?q=GALE
2. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b Completion of enrollment is expected in the second quarter of 2017; 20170515; 20170630; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
3. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b DSMB expects to perform the interim efficacy analysis near the end of 2017; 20171115; 20171231; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
4. Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (HER3+); 20191231; 20201231; https://clinicaltrials.gov/ct2/show/NCT02297698?term=neuvax&rank=1
5. Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer; 20190301; 20190331; https://clinicaltrials.gov/ct2/show/NCT02636582?term=NCT02636582&rank=1

6) ECYT – Endocyte, Inc. – Trading Below Cash
a. Buy at < ~ $1.50
b. Sell at >~ $3.22
c. Catalysts:
1. Phase 1 data for EC1456 and EC1169; 2016; ;

7) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.11
b. Sell at >~ $2.45

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 06/26/2017 – 06/30/2017, and Why?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 07/17/2017 – 07/21/2017:

1) ATEC – Alphatec Holdings Inc – Trading Below Cash
a. Buy at < ~ $1.62
b. Sell at >~ $5.80

2) UNXL – Uni-Pixel Inc
a. Buy at < ~ $0.35
b. Sell at >~ $0.60

3) TRIL – Trillium Therapeutics Inc.
a. Buy at < ~ $4.15
b. Sell at >~ $6.90
c. Catalysts:
1. Phase 2 – Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer; 20170930; 20170930; https://ClinicalTrials.gov/show/NCT01010126
2. NA – A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting; 20170815; 20181030; https://ClinicalTrials.gov/show/NCT02364531
3. Phase 3 – Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery; 20180101; 20180131; https://ClinicalTrials.gov/show/NCT00324805
4. Phase 3 – Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial); 20171231; 20171231; https://ClinicalTrials.gov/show/NCT00310180
5. Phase 1Phase 2 – Thoracic Surgery Extended Low-Molecular Weight Heparin VTE Prophylaxis–Pilot Trial; 20170601; 20170831; https://ClinicalTrials.gov/show/NCT02334007
6. Phase 3 – Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer; 20140601; 20200630; https://ClinicalTrials.gov/show/NCT00066703
7. Phase 3 – A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer; 20110513; 20220312; https://ClinicalTrials.gov/show/NCT00567190
8. Phase 4 – Diabetes Care Management Compared to Standard Diabetes Care in Adolescents and Young Adults With Type 1 Diabetes; 20170501; 20171031; https://ClinicalTrials.gov/show/NCT01351857
9. Phase 3 – Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer; 20150201; 20171231; https://ClinicalTrials.gov/show/NCT00265850
10. Phase 3 – Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer; 20180501; 20180531; https://ClinicalTrials.gov/show/NCT00463489
11. Phase 3 – A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer; 20200101; 20200731; https://ClinicalTrials.gov/show/NCT01101438
12. NA – Womens Initiative Supporting Health Increasing Healthcare Access; 20190601; 20190731; https://ClinicalTrials.gov/show/NCT02964845
13. Phase 3 – Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer; 20220201; 20220228; https://ClinicalTrials.gov/show/NCT01272037
14. Phase 3 – High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery; 20200601; 20200601; https://ClinicalTrials.gov/show/NCT02506153
15. Phase 1 – A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors; 20190601; 20190630; https://ClinicalTrials.gov/show/NCT02663518
16. Phase 1 – Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides; 20181201; 20191231; https://ClinicalTrials.gov/show/NCT02890368
17. Phase 3 – Effect of MD1003 in Progressive Multiple Sclerosis (SPI2); 20180901; 20190930; https://ClinicalTrials.gov/show/NCT02936037
18. Phase 3 – Field Randomization of NA-1 Therapy in Early Responders; 20190301; 20190531; https://ClinicalTrials.gov/show/NCT02315443
19. Phase 3 – FIBrinogen REplenishment in Surgery; 20190130; 20190330; https://ClinicalTrials.gov/show/NCT03037424

4) EGLT – Egalet Corp – Trading Below Cash
a. Buy at < ~ $1.32
b. Sell at >~ $2.00
c. Catalysts:
1. Phase 3 to be completed 4Q 2017. NDA planned for 2018. – Egalet-002 – Moderate to severe chronic pain – Phase 3; 20171001; 20171231; http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=11315453&type=HTML&symbol=EGLT&companyName=Egalet+Corporation&formType=8-K&dateFiled=2017-01-09

5) GALE – Galena Biopharma Inc – Trading Below Cash
a. Buy at < ~ $0.53
b. Sell at >~ $0.79
c. Catalysts:
1. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b DSMB expects to perform the interim efficacy analysis near the end of 2017; 20171115; 20171231; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
2. Q2 2017 Galena Biopharma Inc Earnings Release (Estimated)
-; 20170807; 20170807; https://www.google.com/finance?q=GALE
3. Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (HER3+); 20191231; 20201231; https://clinicaltrials.gov/ct2/show/NCT02297698?term=neuvax&rank=1
4. Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer; 20190301; 20190331; https://clinicaltrials.gov/ct2/show/NCT02636582?term=NCT02636582&rank=1

6) ANTH – Anthera Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $1.47
b. Sell at >~ $2.05
c. Catalysts:
1. Phase 4 – EASY: Extended Access to Sollpura Over Years; 20170901; 20171231; https://ClinicalTrials.gov/show/NCT02823964
2. Phase 2 primary endpoint not met following interim analysis. Trial to continue. Data due 3Q 2017. – Blisibimod – IgA nephropathy – Phase 2; 20170630; 20170930; http://investor.anthera.com/releasedetail.cfm?ReleaseID=1025900
3. Phase 3 – BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy; 20161001; 20211031; https://ClinicalTrials.gov/show/NCT02052219
4. Phase 3 – CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis; 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02074020
5. Phase 3 data due end of 2017 or early 2018. – Sollpura – RESULT – Exocrine pancreatic insufficiency – Phase 3; 20180331; 20180331; http://files.shareholder.com/downloads/ABEA-3R5RJ7/2039745217x0x948640/5EE14DFC-C765-43AD-B65D-BC5471C38EB7/ANTH_News_2017_7_6_General_Releases.pdf
6. Phase 3 – RESULT: Reliable, Emergent Solution Using Liprotamase Treatment; 20171101; 20171231; https://ClinicalTrials.gov/show/NCT03051490

7) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.11
b. Sell at >~ $2.45

8) SRRA – Sierra Oncology, Inc.
a. Buy at < ~ $1.10
b. Sell at >~ $1.35
c. Catalysts:
1. Phase 3 – A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower130); 20171201; 20181015; https://ClinicalTrials.gov/show/NCT02367781
2. Phase 4 – Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE; 20171201; 20171231; https://ClinicalTrials.gov/show/NCT01491763
3. Phase 3 – A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]; 20180101; 20230215; https://ClinicalTrials.gov/show/NCT02367794
4. N/A – Current Treatment of HCV Infection After HSCT; 20180601; 20180731; https://ClinicalTrials.gov/show/NCT03014986
5. N/A – ClariCoreâ„¢ Biopsy System in Patients Undergoing Radical Retropubic Prostatectomy; 20180501; 20181231; https://ClinicalTrials.gov/show/NCT02773940
6. N/A – ClariCore Optical Biopsy System Used in TRUS (Trans-Rectal Ultrasound)-Guided Prostrate Biopsy; 20170901; 20171231; https://ClinicalTrials.gov/show/NCT02928640
7. Phase 2 – PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine); 20160901; 20180731; https://ClinicalTrials.gov/show/NCT02226965
8. Phase 3 – Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer; 20140401; 20171231; https://ClinicalTrials.gov/show/NCT00288080
9. Phase 3 – A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer; 20170601; 20180630; https://ClinicalTrials.gov/show/NCT01322490
10. Phase 1/Phase 2 – Prophylactic Infusion of Donor Lymphocytes in Cord Blood Transplantation; 20170701; 20180731; https://ClinicalTrials.gov/show/NCT02328885
11. N/A – S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases; 20170701; 20170731; https://ClinicalTrials.gov/show/NCT00874211
12. Phase 2 – Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA); 20180731; 20180731; https://ClinicalTrials.gov/show/NCT02833350
13. Phase 3 – Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT); 20191031; 20191031; https://ClinicalTrials.gov/show/NCT02745119
14. Phase 3 – Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia; 20190901; 20210930; https://ClinicalTrials.gov/show/NCT02785900
15. Phase 3 – A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen; 20220131; 20220131; https://ClinicalTrials.gov/show/NCT02066636
16. N/A – Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms; 20261001; 20261031; https://ClinicalTrials.gov/show/NCT00443274
17. N/A – Connect® MM- The Multiple Myeloma Disease Registry; 20241201; 20241231; https://ClinicalTrials.gov/show/NCT01081028
18. Phase 4 – Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis; 20190808; 20190808; https://ClinicalTrials.gov/show/NCT02092467
19. N/A – Connectâ„¢ CLL: The Chronic Lymphocytic Leukemia Disease Registry; 20190101; 20190131; https://ClinicalTrials.gov/show/NCT01081015
20. Phase 3 – Study Of Diabetic Nephropathy With Atrasentan; 20180731; 20200408; https://ClinicalTrials.gov/show/NCT01858532
21. Phase 1 – A Phase 1 Trial of SRA737 in Subjects With Advanced Cancer; 20190201; 20190228; https://ClinicalTrials.gov/show/NCT02797964
22. Phase 3 – Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML; 20190601; 20190630; https://ClinicalTrials.gov/show/NCT02665065
23. Phase 1 – A Phase 1 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer; 20190401; 20190430; https://ClinicalTrials.gov/show/NCT02797977

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 07/17/2017 – 07/21/2017, and Why?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowCash (#TBC) as of 07/14/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Cash/sh = $1.81
2. $AVIR – Aviragen Therapeutics Inc :
   1. Cash/sh = $0.97
3. $DMTX – Dimension Therapeutics Inc :
   1. Cash/sh = $2.36
4. $EARS – Auris Medical Holding AG :
   1. Cash/sh = $1.12
5. $ECYT – Endocyte, Inc. :
   1. Cash/sh = $2.91
6. $OPHT – Ophthotech Corp :
   1. Cash/sh = $6.30
7. $OREX – Orexigen Therapeutics, Inc. :
   1. Cash/sh = $5.82
8. $ROKA – Roka Bioscience Inc :
   1. Cash/sh = $3.19
9. $TEAR – TearLab Corp :
   1. Cash/sh = $2.20
10. $TNDM – Tandem Diabetes Care Inc :
    1. Cash/sh = $0.92

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook ( #TBB ) as of 07/14/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Book/sh = $1.71
2. $AVIR – Aviragen Therapeutics Inc :
   1. Book/sh = $0.63
3. $DMTX – Dimension Therapeutics Inc :
   1. Book/sh = $1.90
4. $ECYT – Endocyte, Inc. :
   1. Book/sh = $2.99
5. $KTOV – Kitov Pharmaceuticals Holdings Ltd :
   1. Book/sh = $1.80
6. $LBIX – Leading Brands, Inc (USA) :
   1. Book/sh = $1.81
7. $ROKA – Roka Bioscience Inc :
   1. Book/sh = $5.93
8. $TNXP – Tonix Pharmaceuticals Holding Corp. :
   1. Book/sh = $5.51

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Author]

Posts